Michael B. Atkins, MD, of the Lombardi Comprehensive Cancer Center, discusses treatment-free survival outcomes from the phase 2 HCRN GU16-260 study and what the data tell us for immunotherapy applicability in favorable-risk patients.
HCRN GU16-260: Nivolumab, Salvage Nivo/Ipi in Advanced Clear Cell RCC
By Michael B. Atkins, MD - Last Updated: March 10, 2023Post Tags:ASCO GU 2023-Renal Cell Carcinoma
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.